Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,977 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.
Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D. Venkatesan AM, et al. Among authors: baker j. J Med Chem. 2004 Dec 2;47(25):6255-69. doi: 10.1021/jm040086x. J Med Chem. 2004. PMID: 15566296
Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB. Aranapakam V, et al. Among authors: baker j. J Med Chem. 2003 Jun 5;46(12):2376-96. doi: 10.1021/jm0205550. J Med Chem. 2003. PMID: 12773042
Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R. Aranapakam V, et al. Among authors: baker jl. J Med Chem. 2003 Jun 5;46(12):2361-75. doi: 10.1021/jm0205548. J Med Chem. 2003. PMID: 12773041
Measurement Invariance on the Nine-Item Avoidant/Restrictive Food Intake Disorder Screen (NIAS) by Age and Reporter Status: Comparing ARFID Symptoms Among Self-Reporting Adults and Adolescents and Parent Reports of Children and Adolescents.
Barnhart WR, Hog L, Zickar MJ, Baker JH, Dinkler L, Guintivano J, Johnson JS, MacDermod C, Munn-Chernoff M, Micali N, Ortiz S, Pisetsky EM, White JP, Bulik CM, Thornton LM. Barnhart WR, et al. Among authors: baker jh. Int J Eat Disord. 2025 Jan 19. doi: 10.1002/eat.24381. Online ahead of print. Int J Eat Disord. 2025. PMID: 39829155
Prevalence and clinical impact of the London classification: a prospective, international, multicenter study from the Lower Gastrointestinal International Consortium (LoGIC).
Vollebregt PF, Heitmann PT, Damon H, Garcia-Zermeño K, Garcia FD, Baker J, Schloithe A, Moshiree B, Remes-Troche JM, Mion F, Dinning PG, Knowles CH, Scott SM. Vollebregt PF, et al. Among authors: baker j. Am J Gastroenterol. 2025 Jan 16. doi: 10.14309/ajg.0000000000003320. Online ahead of print. Am J Gastroenterol. 2025. PMID: 39819766
7,977 results